Elongation factor 2 in cancer: a promising therapeutic target in protein translation.

Autor: Jia X; Henan International Joint Laboratory of TCM Syndrome and Prescription in Signaling, Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan, China.; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, China., Huang C; Henan International Joint Laboratory of TCM Syndrome and Prescription in Signaling, Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan, China.; Department of Pathology and Pathophysiology, School of Medicine, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan, China., Liu F; Department of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, China. ffliu89@zzu.edu.cn., Dong Z; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, China. dongzg@zzu.edu.cn.; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, Henan, China. dongzg@zzu.edu.cn.; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, 450001, Henan, China. dongzg@zzu.edu.cn.; The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, 450000, Henan, China. dongzg@zzu.edu.cn., Liu K; Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, China. kdliu@zzu.edu.cn.; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, Henan, China. kdliu@zzu.edu.cn.; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou, 450001, Henan, China. kdliu@zzu.edu.cn.; The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, 450000, Henan, China. kdliu@zzu.edu.cn.
Jazyk: angličtina
Zdroj: Cellular & molecular biology letters [Cell Mol Biol Lett] 2024 Dec 20; Vol. 29 (1), pp. 156. Date of Electronic Publication: 2024 Dec 20.
DOI: 10.1186/s11658-024-00674-7
Abstrakt: Aberrant elongation of proteins can lead to the activation of oncogenic signaling pathways, resulting in the dysregulation of oncogenic signaling pathways. Eukaryotic elongation factor 2 (eEF2) is an essential regulator of protein synthesis that precisely elongates nascent peptides in the protein elongation process. Although studies have linked aberrant eEF2 expression to various cancers, research has primarily focused on its structure, highlighting a need for deeper exploration into its molecular functions. In this review, recent advancements in the structure, guanosine triphosphatase (GTPase) activity, posttranslational modifications, regulatory factors, and inhibitors of eEF2 are summarized. These findings provide a comprehensive cognition on the critical role of eEF2 and its potential as a therapeutic target in cancer. Furthermore, this review highlights important unanswered questions that warrant investigation in future research.
Competing Interests: Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: